Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Launched by REVOLUTION MEDICINES, INC. · May 13, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called RMC-6236 for adults with advanced solid tumors that have specific mutations in a gene known as RAS. This includes types of cancer like non-small cell lung cancer, colorectal cancer, and pancreatic cancer. The main goal of the trial is to determine how safe RMC-6236 is and how well patients can tolerate it.

To join the study, patients need to have a confirmed diagnosis of an advanced solid tumor with specific mutations in the KRAS gene, and they should have already received standard treatments for their cancer. Participants should be between the ages of 65 and 74, and they must be in good overall health, as measured by a performance status scale. Throughout the trial, participants can expect regular check-ins to monitor their health and any side effects from the treatment. It's important to note that individuals with certain medical conditions, such as untreated brain tumors or significant gastrointestinal issues, may not be eligible for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing. PDAC with wild-type RAS (expansion).
• • Received prior standard therapy appropriate for tumor type and stage
• • Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• • Adequate organ function
• Exclusion Criteria:
• • Primary central nervous system (CNS) tumors
• • Active, untreated brain metastases
• • Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
• • History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy
• • Other inclusion/exclusion criteria may apply.